Am­gen’s win for a Ste­lara in­ter­change­able biosim­i­lar prompts ques­tions about ‘mean­ing­ful com­pe­ti­tion’ un­der IRA

The FDA ap­proval of Am­gen’s in­ter­change­able Ste­lara biosim­i­lar is rais­ing broad­er ques­tions about how po­ten­tial com­pe­ti­tion could im­pact Medicare price ne­go­ti­a­tions for John­son & John­son …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER